临床药物遗传学实施联盟 HLA-B 基因型和阿巴卡韦剂量指南：2014 年更新。
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
机构信息
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2014 May;95(5):499-500. doi: 10.1038/clpt.2014.38. Epub 2014 Feb 21.
Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
摘要
临床药物遗传学实施联盟（CPIC）关于 HLA-B 基因型和阿巴卡韦剂量的指南最初于 2012 年 4 月发布。我们回顾了最近的文献，得出的结论是，没有任何证据会改变原始指南中的治疗建议；因此，原始出版物仍然具有临床时效性。然而，我们已经更新了在线补充材料，并为将 CPIC 指南应用于电子健康记录添加了额外的资源。最新信息可在 PharmGKB（http://www.pharmgkb.org）上找到。
相似文献
1
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
Clin Pharmacol Ther. 2014 May;95(5):499-500. doi: 10.1038/clpt.2014.38. Epub 2014 Feb 21.
2
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.
Clin Pharmacol Ther. 2016 Jan;99(1):36-7. doi: 10.1002/cpt.161. Epub 2015 Jul 16.
3
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.
4
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.
5
Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.
Clin Pharmacol Ther. 2013 Sep;94(3):324-8. doi: 10.1038/clpt.2013.103. Epub 2013 May 21.
6
The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.
Clin Pharmacol Ther. 2020 Jan;107(1):171-175. doi: 10.1002/cpt.1651. Epub 2019 Nov 5.
7
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
Clin Pharmacol Ther. 2021 Feb;109(2):302-309. doi: 10.1002/cpt.2008. Epub 2020 Sep 6.
8
Abacavir pharmacogenetics--from initial reports to standard of care.
Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3.
9
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
Pharmacogenet Genomics. 2020 Oct;30(8):167-174. doi: 10.1097/FPC.0000000000000409.
10
Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
Tissue Antigens. 2015 Jul;86(1):28-31. doi: 10.1111/tan.12575. Epub 2015 Apr 29.
引用本文的文献
1
Improved Pharmacogenomic Testing Process for Veterans in Outpatient Settings by Clinical Pharmacist Practitioners.
Fed Pract. 2025 May;42(5):200-203. doi: 10.12788/fp.0554. Epub 2025 May 17.
2
Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care.
Clin Biochem. 2025 Aug 18;139:110992. doi: 10.1016/j.clinbiochem.2025.110992.
3
Vancomycin Drug Reaction with Eosinophilia and Systemic Symptoms: Meta-Analysis and Pharmacovigilance Study.
J Clin Med. 2025 Jan 31;14(3):930. doi: 10.3390/jcm14030930.
4
Pharmacogenetics: Opportunities for the Research Program and Other Large Data Sets to Advance the Field.
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):111-130. doi: 10.1146/annurev-pharmtox-061724-080718.
5
Patterns of pharmacogenetic variation in nine biogeographic groups.
Clin Transl Sci. 2024 Sep;17(9):e70017. doi: 10.1111/cts.70017.
6
Prevalence of the HLA-B*5701 Allele and Abacavir Hypersensitivity in Saudi HIV Patients: A Multicenter Study.
Cureus. 2023 Nov 3;15(11):e48229. doi: 10.7759/cureus.48229. eCollection 2023 Nov.
7
Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners.
Genes (Basel). 2023 Sep 22;14(10):1841. doi: 10.3390/genes14101841.
8
The Implementation of Pharmacogenetics in the United Kingdom.
Handb Exp Pharmacol. 2023;280:3-32. doi: 10.1007/164_2023_658.
9
PAnno: A pharmacogenomics annotation tool for clinical genomic testing.
Front Pharmacol. 2023 Jan 26;14:1008330. doi: 10.3389/fphar.2023.1008330. eCollection 2023.
10
Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.
Methods Mol Biol. 2022;2547:21-45. doi: 10.1007/978-1-0716-2573-6_2.
本文引用的文献
1
HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity.
J Allergy Clin Immunol. 2013 Sep;132(3):756-758. doi: 10.1016/j.jaci.2013.04.013. Epub 2013 May 23.
2
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19.
3
Leveraging the electronic health record to implement genomic medicine.
Genet Med. 2013 Apr;15(4):270-1. doi: 10.1038/gim.2012.131. Epub 2012 Sep 27.
4
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.
5
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.
Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.
6
The emerging role of electronic medical records in pharmacogenomics.
Clin Pharmacol Ther. 2011 Mar;89(3):379-86. doi: 10.1038/clpt.2010.260. Epub 2011 Jan 19.
Zotero 插件